BioPharm Executive: Manufacturing Trouble: Moving From Crisis to Crisis

Wed, 29 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BioPharm Executive: Myriad Genetics, Inc., Glivec, and the $1 Billion "Myth"

Thu, 25 Apr 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BioPharm Executive Speaking the Unspeakable

Wed, 27 Mar 2013 12:00:00 AM GMT

March 27, 2013

Speaking the Unspeakable

This past December, the U.S. Court of Appeals for the Second Circuit handed down a decision in U.S. vs. Alfred Caronia...

BioPharm Executive: 2012 in Review

Wed, 19 Dec 2012 12:00:00 AM GMT
2012 in Review
What important stories shaped this past year...and promise to influence the year ahead? In our tradition of touching on some unscientifically selected highlights...

BioPharm Executive: Pharma Embraces Emerging Markets; They Don't Embrace Back

Wed, 26 Sep 2012 12:00:00 AM GMT
Pharma Embraces Emerging Markets; They Don't Embrace Back
Plus a Modest Patent Proposal

Like most major pharma companies,

BioPharm Executive: Patent Threats, and the Cheap Cost of R&D

Thu, 30 Aug 2012 12:00:00 AM GMT
Patent Threats, and the Cheap Cost of R&D

Myriad Genetics won the latest battle in its long-fought...

BioPharm Executive: 6 Ways to Save Biotech

Wed, 25 Jul 2012 12:00:00 AM GMT
6 Ways to Save Biotech

Here we are a bit past mid-year, and figures from the first half of 2012 point to a rapidly worsening environment for early-stage biotech companies...

BioPharm Executive: The Price of Togetherness

Wed, 27 Jun 2012 12:00:00 AM GMT
The Price of Togetherness

Is togetherness the latest drug? Will touchy feeliness be the answer to the pharmaceutical industry's crisis of productivity? Collaboration certainly...

BioPharm Executive: Your American Society of Clinical Oncology Crib Sheet

Wed, 30 May 2012 12:00:00 AM GMT
Your ASCO Crib Sheet

On your way to Chicago for the annual meeting of the American Society of Clinical...

BioPharm Executive: Shareholders Before Patients?

Wed, 25 Apr 2012 12:00:00 AM GMT
Shareholders Before Patients

It's been a great month for Gilead Sciences in the clinic; when it...

BioPharm Executive: Smaller is Smarter

Wed, 28 Mar 2012 12:00:00 AM GMT
Smaller is Smarter

The Wall Street Journal recently noted that biotech funding is getting

BioPharm Executive: Bubble, Billions, or Both?

Wed, 29 Feb 2012 12:00:00 AM GMT
Bubble, Billions, or Both?

Another month, another batch of big hepatitis C news. Is all the furious dealmaking in the space indicative of biotech's own mini-bubble? Or is...

BioPharm Executive: Embracing Generics and Emerging Markets

Wed, 25 Jan 2012 12:00:00 AM GMT
Embracing Generics and Emerging Markets

Did you know that the average daily cost of drugs dropped by one third between 2005 and 2010? And that Medicare drug spending has...

BioPharm Executive: Top 10: 2011 in Review

Wed, 14 Dec 2011 12:00:00 AM GMT
Top 10: 2011 in Review

Here it is, our fourth annual Top 10 Year in Review--a wholly subjective look at the 10 stories or trends that shaped the year in biotech. Drum roll, please......

BioPharm Executive: The Bad Old Days in Europe?

Wed, 30 Nov 2011 12:00:00 AM GMT
The Bad Old Days in Europe?

As the euro crisis seems to worsen (or simply goes on without resolution), more voices are willing to speak a fear that, even a couple months ago, was...

BioPharm Executive: FDA Gets the Message

Wed, 26 Oct 2011 12:00:00 AM GMT
FDA Gets the Message

We're all familiar with Wall Street banks, major pharmaceutical companies, and other corporations that settle various charges and investigations "without admitting any wrongdoing." Now it seems FDA may be doing something similar...

BioPharm Executive: Too Big to Succeed?

Thu, 29 Sep 2011 12:00:00 AM GMT
Too Big to Succeed?

There's an interesting...

BioPharm Executive: The Price of Confusion

Thu, 01 Sep 2011 12:00:00 AM GMT
The Price of Confusion

It's been a confusing summer. Standard & Poor's now believes U.S. Treasury Bills are riskier than French government debt. British youth violently rioted and looted for days over nothing in particular. The markets have gone...

BioPharm Executive: FDA, Faster Than Ever?

Thu, 28 Jul 2011 12:00:00 AM GMT
FDA, Faster Than Ever?

At the recent BIO annual convention in Washington, D.C., Biotechnology Industry Organization president Jim Greenwood offered up a legislative...

BioPharm Executive: Everything You Wanted to Know About ASCO (But Were Afraid to ASCO)

Wed, 25 May 2011 12:00:00 AM GMT

Biopharm Executive: Too Big to Be Responsible?

Thu, 28 Apr 2011 12:00:00 AM GMT

BioPharm Executive: Pure, Small Pharma

Wed, 30 Mar 2011 12:00:00 AM GMT

BioPharm Executive: We're All In This Together

Wed, 23 Feb 2011 12:00:00 AM GMT

BioPharm Executive: Going Mobile

Thu, 27 Jan 2011 12:00:00 AM GMT

BioPharm Executive: Top 10: 2010 In Review

Wed, 15 Dec 2010 12:00:00 AM GMT

BioPharm Executive: The Acceleration of Disgust

Wed, 24 Nov 2010 12:00:00 AM GMT

BioPharm Executive: Lilly's Shopping Plans Go Against the Grain

Wed, 27 Oct 2010 12:00:00 AM GMT

BioPharm Executive: Is Cancer's "Penicillin Moment" FDA's Moment of Doubt?

Wed, 29 Sep 2010 12:00:00 AM GMT

BioPharm Executive: Lilly, By Any Other Name...

Wed, 25 Aug 2010 12:00:00 AM GMT

BioPharm Executive: Firing Slows, but Lilly Fans the Flames

Thu, 29 Jul 2010 12:00:00 AM GMT

BioPharm Executive: Clean Up Your Act

Wed, 30 Jun 2010 12:00:00 AM GMT

BioPharm Executive: Hurry Up and Wait

Wed, 28 Apr 2010 12:00:00 AM GMT

BioPharm Executive: The New Decade Finally Begins

Wed, 31 Mar 2010 12:00:00 AM GMT

BioPharm Executive: This Is Recovery: Less Money, Less Risk Appetite, Fewer Jobs

Wed, 24 Feb 2010 12:00:00 AM GMT

BioPharm Executive: J.P. Morgan Healthcare Conference Sets the Tone for 2010

Wed, 27 Jan 2010 12:00:00 AM GMT

BioPharm Executive: Top 10: 2009 In Review

Mon, 21 Dec 2009 12:00:00 AM GMT

BioPharm Executive: Where'd the Jobs Go?

Wed, 25 Nov 2009 12:00:00 AM GMT

BioPharm Executive: No Sleep, But Plenty of REMS

Wed, 28 Oct 2009 12:00:00 AM GMT

BioPharm Executive: Vivus: Savior of the Pharma Industry?

Wed, 30 Sep 2009 12:00:00 AM GMT
Vivus: Savior of the Pharma Industry?

Obesity took center stage in September, with important clinical results released on two key products: Vivus Pharmaceuticals

BioPharm Executive: Biotech's Dog Days

Wed, 26 Aug 2009 12:00:00 AM GMT
Biotech's Dog Days

Ah, the dog days of summer...those long, glorious days that make it impossible to get the kids to sleep before 10 PM. They're called the dog days, by the way, because Sirius, the Dog Star and the brightest star in the heavens...

BioPharm Executive: Sunshine, Lollipops, and Exclusivity

Tue, 21 Jul 2009 12:00:00 AM GMT
Sunshine, Lollipops, and Exclusivity

I don't like being a downer, but for the past year or so, that's been an unavoidable hazard of digesting the month's news. So it's nice to see a month like July, which has ushered in plenty of good news for...

BioPharm Executive: Sprinting to the Finish

Tue, 30 Jun 2009 12:00:00 AM GMT

BioPharm Executive: Biotech's Green Shoots

Wed, 27 May 2009 12:00:00 AM GMT

BioPharm Executive: We Are All Activists Now

Wed, 29 Apr 2009 12:00:00 AM GMT

BioPharm Executive -- Biogenerics: The Time Has Come

Tue, 31 Mar 2009 12:00:00 AM GMT
Biogenerics: The Time Has Come

Sorry, Biotechnology Industry Organization, but I just don't think you're going to win the battle on follow-on biologics (FOBs) this...

BioPharm Executive: Big Pharma's Musical Chairs

Wed, 25 Feb 2009 12:00:00 AM GMT
Big Pharma's Musical Chairs

The biggest deal of the past month--and what will perhaps prove to be the biggest deal of the year--came just a little too late for inclusion in last month's issue.

BioPharm Executive: Off On the Right Hand in 2009

Wed, 28 Jan 2009 12:00:00 AM GMT
Off On the Right Hand in 2009

This year's J.P. Morgan Healthcare conference in San Francisco took a sinister turn. When Genentech's Art Levinson took the stage, he...

BioPharm Executive Top 10: 2008 in Review

Thu, 18 Dec 2008 12:00:00 AM GMT
Top 10: 2008 in Review

A lot of us will be glad to see the back of 2008, a year that may have left many families hemming and hawing for something positive to say around the Thanksgiving table, at least as far as the world at large is concerned...

BioPharm Executive: Change Comes to Biotech

Tue, 25 Nov 2008 12:00:00 AM GMT
Change Comes to Biotech

It's beyond me why anyone would want to be President, particularly now, but come January Barrack Obama will take up the troubled mantle of state and probably even do it with a smile on his face.

And...

BioPharm Executive: No Free Lunch

Wed, 29 Oct 2008 12:00:00 AM GMT
No Free Lunch

Looking for free money? Biotech may seem to have just the thing for you. Numerous companies are now trading under their cash value, meaning they could theoretically empty their bank accounts and pay out a dividend greater than their...

BioPharm Executive: There Goes Wall Street

Tue, 30 Sep 2008 12:00:00 AM GMT
There Goes Wall Street

It's difficult to even think about the life sciences industry these days...many of us have one eye glued to CSPAN and the other to our dwindling 401(k) accounts. Drug company execs that recently toured Congressional...

BioPharm Executive: Biotech Money Goes to Democrats (Plus the Stupid Drug Name Olympics)

Wed, 27 Aug 2008 12:00:00 AM GMT
Biotech Money Goes to Democrats
(Plus the Stupid Drug Name Olympics)

It's a small sign of the times.
When he was a Republican congressman from Pennsylvania, Jim Greenwood had a reputation as a social moderate and a fiscal conservative...

BioPharm Executive: Rethink Everything

Wed, 30 Jul 2008 12:00:00 AM GMT
Rethink Everything

Hold onto those pens and squeezy toys! In a few years, they could become eBay collectors' items. The Pharmaceutical Research and Manufacturers of America (PhRMA) put out its revised

Small is Beautiful -- BioPharm Executive

Wed, 25 Jun 2008 12:00:00 AM GMT
Small is Beautiful

Perhaps most men, to paraphrase Henry David Thoreau, indeed lead lives of quiet desperation. Pharmaceutical companies, however, are getting increasingly noisy about it. The patent expiration time bomb is ticking away...

Taking the Gloves Off

Mon, 26 May 2008 12:00:00 AM GMT
By Karl Thiel -- Poor Amgen has got a lot to answer for this month. The new Ernst & Young 2008 Global Biotechnology Report reveals that in 2007, the entire biotech industry lost just $300 million in aggregate. That's the closest it has ever come to profitability. But E&Y had expected it to break into the black for...

Biotech Blossoms Anew

Wed, 30 Apr 2008 12:00:00 AM GMT
Biotech Blossoms Anew
by Karl Thiel (from the BioSpace Inside Recruiter)

A month ago, things looked bleak in the biotech sector. So bleak, in fact, that I suggested investors might want to go against the herd and start nibbling away at stocks...

Time to Buy Biotech?

Wed, 26 Mar 2008 12:00:00 AM GMT
Time to Buy Biotech?

Okay, we know the market has been a brutal, whipsaw place for the past several months. And we know a lot of the forces behind that transcend the issues and concerns of a specific industry. But why is biotech getting handed...

Biogenerics in '08?

Tue, 26 Feb 2008 12:00:00 AM GMT

Biogenerics in '08?

Burnt out on the 2008 race for the White House before the contestants are even selected? I hear...

Keeping Your Hands Clean

Wed, 23 Jan 2008 12:00:00 AM GMT

Keeping Your Hands Clean

Let's start with a summary of the events so far: After a nearly two-year delay,

Desperate But Not Crazy

Thu, 20 Dec 2007 12:00:00 AM GMT

Desperate But Not Crazy

There are all sorts of eulogies being written on the passing golden age of Big Pharma-...

Dinosaurs and Drug Companies

Tue, 20 Nov 2007 12:00:00 AM GMT

Dinosaurs and Drug Companies

If all goes to plan, we'll soon be bidding adieu to

Party Like It's 1999

Tue, 23 Oct 2007 12:00:00 AM GMT

Party Like It's 1999

Ooh, don't you just hate feeling like you're missing the party? I remember being at a biotech conference...

BioSpace.com News

BioPharm Executive: Manufacturing Trouble: Moving From Crisis to Crisis

BioPharm Executive: Myriad Genetics, Inc., Glivec, and the $1 Billion "Myth"

BioPharm Executive Speaking the Unspeakable

BioPharm Executive: 2012 in Review

BioPharm Executive: Pharma Embraces Emerging Markets; They Don't Embrace Back

BioPharm Executive: Patent Threats, and the Cheap Cost of R&D

BioPharm Executive: 6 Ways to Save Biotech

BioPharm Executive: The Price of Togetherness

BioPharm Executive: Your American Society of Clinical Oncology Crib Sheet

BioPharm Executive: Shareholders Before Patients?

BioPharm Executive: Smaller is Smarter

BioPharm Executive: Bubble, Billions, or Both?

BioPharm Executive: Embracing Generics and Emerging Markets

BioPharm Executive: Top 10: 2011 in Review

BioPharm Executive: The Bad Old Days in Europe?

BioPharm Executive: FDA Gets the Message

BioPharm Executive: Too Big to Succeed?

BioPharm Executive: The Price of Confusion

BioPharm Executive: FDA, Faster Than Ever?

BioPharm Executive: Everything You Wanted to Know About ASCO (But Were Afraid to ASCO)

Biopharm Executive: Too Big to Be Responsible?

BioPharm Executive: Pure, Small Pharma

BioPharm Executive: We're All In This Together

BioPharm Executive: Going Mobile

BioPharm Executive: Top 10: 2010 In Review

BioPharm Executive: The Acceleration of Disgust

BioPharm Executive: Lilly's Shopping Plans Go Against the Grain

BioPharm Executive: Is Cancer's "Penicillin Moment" FDA's Moment of Doubt?

BioPharm Executive: Lilly, By Any Other Name...

BioPharm Executive: Firing Slows, but Lilly Fans the Flames

BioPharm Executive: Clean Up Your Act

BioPharm Executive: Hurry Up and Wait

BioPharm Executive: The New Decade Finally Begins

BioPharm Executive: This Is Recovery: Less Money, Less Risk Appetite, Fewer Jobs

BioPharm Executive: J.P. Morgan Healthcare Conference Sets the Tone for 2010

BioPharm Executive: Top 10: 2009 In Review

BioPharm Executive: Where'd the Jobs Go?

BioPharm Executive: No Sleep, But Plenty of REMS

BioPharm Executive: Vivus: Savior of the Pharma Industry?

BioPharm Executive: Biotech's Dog Days

BioPharm Executive: Sunshine, Lollipops, and Exclusivity

BioPharm Executive: Sprinting to the Finish

BioPharm Executive: Biotech's Green Shoots

BioPharm Executive: We Are All Activists Now

BioPharm Executive -- Biogenerics: The Time Has Come

BioPharm Executive: Big Pharma's Musical Chairs

BioPharm Executive: Off On the Right Hand in 2009

BioPharm Executive Top 10: 2008 in Review

BioPharm Executive: Change Comes to Biotech

BioPharm Executive: No Free Lunch

BioPharm Executive: There Goes Wall Street

BioPharm Executive: Biotech Money Goes to Democrats (Plus the Stupid Drug Name Olympics)

BioPharm Executive: Rethink Everything

Small is Beautiful -- BioPharm Executive

Taking the Gloves Off

Biotech Blossoms Anew

Time to Buy Biotech?

Biogenerics in '08?

Keeping Your Hands Clean

Desperate But Not Crazy

Dinosaurs and Drug Companies

Party Like It's 1999